Alot of volume in last days probably due in part to new strong buys in USA by Charles Schwab and Reuters with eps estimate of 56 cents. AT P.E of 20-25 this is sp of $11.20-$14 which could happen in medium term. Short term $8-9.Either way with first approved treatment for DME this is a tiny market cap unrecognized by investors with big potential in a $1.5-$4 billion market.I guess Pfizer knows alot and may be increasing its shares and then make a pitch for company
Add to My Watchlist
What is My Watchlist?